Nov 26

With increased toxicity treatment for amenorrhea.

With increased toxicity, to avoid the delivery of radiation need extremely precise. existed decades breast conserving therapy for early stage breast cancer, a lumpectomy six weeks of whole breast radiation therapy, it has a growing interest in using. Of APBI that treats only the tumor cavity and the surrounding tissue, reducing the treatment of six weeks to five days and the amount of the radiation reduce supplied healthy tissue and adjacent structures treatment for amenorrhea .

The consensus statement of the American Society for Radiation Oncology outlines patient selection criteria and best practices for the use of APBI, a simpler, much shorter course of radiation after lumpectomy surgery for breast cancer. It was in the 15th July 2009 issue of the International Journal of Radiation Oncology* Biology* Physics, Official Journal of the organization. – ‘Patient selection for APBI is a critical part of the treatment decision-making process if wrong patients are selected, occur poor results Said Coral Quiet, MD of Arizona Breast Cancer Specialists The ASTRO consensus statement is a positive step in establishing guidelines for. Patients patients. ‘the doctors the doctors of Arizona Breast Cancer Specialists a a statement of the main conclusions was the importance of ‘limiting the dose to non-target tissues.’The goal is now also with radiation inside the breast through multi – catheter breast brachytherapy techniques such as the SAVI applicator supplied.

$ 628 thousand Pharmaceuticals Receives FDA clearance generic Toprol XL 25 mg and 50 mg.

Forward-Looking StatementAll statements in this press release that to future events or other non-historical facts contains forward-looking statements Empire Watson current perspective of existing trends and information of the date of this news release. The law by law, Empire disclaims any intent or obligation to update such forward-looking statements. The actual results could differ. By Watson current expectations depending on a range of factor, which Empire – fiscal These factors include, among others, the the impact of competitive products and pricing alternatives, market acceptance and the continued demand by Watson products, difficulties or delays in which output and the difficulty which predicting the timing or the results of FDA or other regulatory certificate or actions if found, and risks and uncertainties at the regular public Empire with the U.S. Securities and Exchange Commission, including detailed, but non to the Quarterly Report on Form 10 – Q Watson on the period ended 30 In Jun. 2009 limited.